Skip to main content

David Martinez Selva

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

David Martinez Selva

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Grup de Recerca en Diabetis i Metabolisme

IP: Rafael Simó Canonge
Collaborators: Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Andreea Ciudin Mihai
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 43680
Reference: 2009 SGR 739
Duration: 01/01/2010 - 30/04/2014

Sex hormone-binding globulin (SHBG): Identification of the molecular mechanisms that regulate its expression and role in body fat distribution and in the development of type 2 diabetes

IP: Rafael Simó Canonge
Collaborators: David Martinez Selva, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 247050
Reference: MS08/00058
Duration: 01/02/2009 - 31/01/2015

Sex hormone-binding globulin (SHBG): Identification of the molecular mechanisms that regulate its expression and role in body fat distribution and in the development of type 2 diabetes

IP: David Martinez Selva
Collaborators: Rafael Simó Canonge, Cristina Hernández Pascual
Funding agency: Instituto de Salud Carlos III
Funding: 42000
Reference: CP08/00058
Duration: 01/01/2009 - 31/12/2011

Identificación de los mecanismos moleculares que regulan la expresión de la Sex hormone-binding globulin (SHBG) en el desarrollo y progresión de la diabetes de tipo 2 y de la distrución de la grasa corporal

IP: Rafael Simó Canonge
Collaborators: David Martinez Selva, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: CP07/00180
Duration: -

Related news

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Related professionals

Kerrie Adrián Campbell

Kerrie Adrián Campbell

Research technician
Neurovascular Diseases
Read more
Novica Nikolic

Novica Nikolic

Research assistant
Clinical Research/Innovation in Pneumonia & Sepsis (CRIPS)
Read more
Laia Yañez Bisbe

Laia Yañez Bisbe

Postdoctoral researcher
Cardiovascular Diseases
Read more
Bernat Serra Creus

Bernat Serra Creus

Predoctoral researcher
Cardiovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.